Comparison of postoperative nausea and vomiting with remimazolam and propofol

Comparison of postoperative nausea and vomiting with remimazolam and propofol - Comparison of postoperative nausea and vomiting with remimazolam and propofol

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044442

Enrollment

Registered

2021-06-05

Start date

2021-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Remimazolam group. Propofol group.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Female patients over 20 years of age undergoing unilateral mastectomy. Ability to obtain informed consent. ASA classification 1 or 2.

Exclusion criteria

Exclusion criteria: Contraindication to application of both remimazolam besylate and propofol. Contraindication to regional anesthesia. BMI higher than 35 kg/m2.

Design outcomes

Primary

Measure	Time frame
Frequency of postoperative nausea and vomiting from immediately after surgery to the second postoperative day.	—

Secondary

Measure	Time frame
Comparison of vascular pain, circulatory depression (bradycardia, hypotension), intraoperative arousal, and postoperative complications (respiratory depression, delayed arousal, delirium, shivering, erythema and headache).	—

Countries

Japan

Contacts

Public ContactChie Hirose

Suwa Red-Cross Hospital Anesthesiology

chirose@shinshu-u.ac.jp0266576062

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026